Finerenone
Finerenone 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Chronic Kidney Disease、Proteinuria、Children。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
12 项
已进入 III/IV 期
30 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Bayer
- University of Texas Southwestern Medical Center
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Colorado Prevention Center
- University of North Carolina, Chapel Hill
- Botkin Hospital
- Steno Diabetes Center Copenhagen
- Chinese University of Hong Kong
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Russia、德国、日本、中国台湾、西班牙、Argentina、Brazil、加拿大、Croatia、Czechia、Greece
正在招募患者的 Finerenone 研究
Polypill for Prevention of Cardiomyopathy
I 期 / II 期招募中美国NCT06143566Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
II 期招募中RussiaNCT06655480An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
不适用招募中美国德国日本中国台湾NCT06278207An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
不适用招募中西班牙NCT07554469A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
III 期招募中美国ArgentinaBrazil加拿大NCT06033950The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
II 期招募中美国NCT06059664A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
III 期招募中美国Argentina澳大利亚奥地利NCT05457283A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
III 期招募中美国Brazil加拿大中国NCT06024746Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
不适用招募中RussiaNCT07056595Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
III 期招募中丹麦NCT06082063Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
IV 期招募中中国香港NCT06727409A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
IV 期招募中丹麦德国西班牙瑞典NCT07239570Finerenone After Catheter Ablation to Reduce Atrial Fibrillation Recurrence
II 期招募中中国台湾NCT07799519Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure
IV 期招募中日本NCT07397650Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.
IV 期招募中丹麦NCT07026539Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
不适用招募中德国NCT02378805Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
IV 期招募中中国NCT07315191Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
III 期招募中中国NCT07575672The MICRON Study - A Steno 1 Substudy
不适用招募中丹麦NCT07270172Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
IV 期招募中中国NCT06573411Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease
不适用招募中中国NCT06838416Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
II 期招募中丹麦NCT06906081Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism
不适用招募中BangladeshNCT07688928The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
III 期招募中澳大利亚India新西兰西班牙NCT06058585
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。